Primary Biliary Cholangitis (PBC)

📋 Key Information Summary

📋

Primary biliary cholangitis (PBC) is a chronic, immune-mediated granulomatous destruction of intrahepatic bile ducts, predominantly affecting middle-aged women (F:M ratio ≈ 9:1).
Diagnosis requires two of three criteria: antimitochondrial antibody (AMA) positivity (or PBC-specific ANA against sp100/gp210), cholestatic LFTs persisting >6 months, and histologically compatible liver biopsy.
IgM elevation is a characteristic (though not diagnostic) laboratory feature. Imaging must exclude extrahepatic biliary obstruction before diagnosis.
Liver biopsy is reserved for AMA-negative patients, those with PBC-specific ANA only, or when overlap syndromes (e.g., PBC-AIH) are suspected.
First-line therapy is ursodeoxycholic acid (UDCA) at 13–15 mg/kg/day; biochemical response is assessed at 12 months using POISE, GLOBE, UK-PBC, or Paris II criteria.
Inadequate UDCA responders should receive second-line obeticholic acid (OCA) 5–10 mg daily; OCA is contraindicated in decompensated cirrhosis or portal hypertension due to risk of hepatic decompensation.
Bezafibrate 400 mg/day (off-label) can be added to UDCA in suboptimal responders, with evidence from the BEZURSO and POISE trials.
Emerging agents — seladelpar (recently FDA-approved) and elafibranor — show promise as add-on therapies for inadequate UDCA responders.
Pruritus management follows a stepwise approach: cholestyramine (1st-line), rifampicin (2nd-line with LFT monitoring), sertraline, then naltrexone; refractory cases may require plasmapheresis or transplant.
Fatigue has no proven pharmacotherapy; address modifiable contributors (depression, hypothyroidism, anaemia, sleep disorders).
Osteoporosis screening with DEXA at diagnosis and every 2 years; fat-soluble vitamin (A, D, E, K) levels should be monitored, especially in advanced disease.
Hepatocellular carcinoma (HCC) surveillance with 6-monthly ultrasound is indicated in patients with PBC-related cirrhosis.
Liver transplantation is indicated for end-stage PBC (MELD ≥15 or decompensation); disease recurrence post-transplant occurs in 10–30% of patients.
Aboriginal and Torres Strait Islander peoples may present later with more advanced disease; culturally safe, multidisciplinary care improves outcomes.

Introduction & Australian Epidemiology

Primary biliary cholangitis (PBC) — previously termed primary biliary cirrhosis — is a chronic, autoimmune cholestatic liver disease characterised by progressive, immune-mediated destruction of intrahepatic small bile ducts. The name was officially changed in 2015 to better reflect the disease spectrum, as many patients never develop cirrhosis.

PBC is the most common autoimmune liver disease in the developed world. Key epidemiological features include:

Prevalence: Estimated at 15–40 per 100,000 in Australia, broadly consistent with international data (19–400 per 100,000 globally).
Sex ratio: Female-to-male ratio approximately 9:1; approximately 90% of patients are female.
Age: Median age at diagnosis is 50–55 years, though PBC can present at any age including in the paediatric population (rare).
Trends: Incidence is increasing globally, partly due to improved detection of early/asymptomatic disease. Australian registry data suggest stable incidence over the past decade.
Geographic variation: Higher prevalence in Northern European populations; prevalence in Aboriginal and Torres Strait Islander peoples is not well characterised but is likely under-recognised.
Comorbidities: Strong association with other autoimmune conditions — Sjögren syndrome (up to 75%), autoimmune thyroid disease, Raynaud phenomenon, coeliac disease, and scleroderma/CREST syndrome.

⚠️

Australian AMR & access note: PBC treatment relies on immunomodulatory and bile-acid therapies rather than antibiotics. However, rifampicin for pruritus should be prescribed with awareness of emerging mycobacterial resistance patterns. Obeticholic acid is available via PBS Authority Required status. Always confirm current PBS listings via Services Australia.

Diagnosis

The diagnosis of PBC is made when a patient fulfils two of three criteria in the absence of other causes of cholestasis:

1

Positive serology

Antimitochondrial antibody (AMA) positive at a titre ≥1:40 by indirect immunofluorescence, OR PBC-specific antinuclear antibodies (ANA) — anti-sp100 or anti-gp210 antibodies by ELISA/immunoblot.

2

Biochemical evidence

Cholestatic liver function tests (predominantly elevated alkaline phosphatase [ALP] and gamma-glutamyl transferase [GGT]) persisting for >6 months, disproportionate to transaminase elevation.

3

Histological evidence

Liver biopsy demonstrating florid duct lesions (granulomatous destruction of interlobular bile ducts) or characteristic features on Ludwig or Scheuer staging.

Investigations

Essential

Antimitochondrial antibody (AMA)

Sensitivity 95%, specificity 98% for PBC. Available at all major Australian pathology services. MBS item 69484 (immunological tests). Positive in ~95% of PBC patients.

Essential

Liver function tests (ALP, GGT, ALT, AST, bilirubin)

Cholestatic pattern: ALP elevated ≥2× ULN with disproportionate GGT. Transaminases may be mildly elevated. Bilirubin normal in early disease but rises in advanced stages. MBS item 66500.

Available

PBC-specific ANA (anti-sp100, anti-gp210)

Present in ~30% of AMA-negative PBC patients and ~25–30% of AMA-positive patients. Refer to specialist immunology laboratory. Available at major reference labs in Melbourne, Sydney, Brisbane.

Available

Immunoglobulins (particularly IgM)

Elevated IgM is characteristic of PBC (found in ~70% of patients) but not diagnostic. MBS item 65070.

Essential

Abdominal ultrasound ± MRCP

Mandatory to exclude extrahepatic biliary obstruction (e.g., gallstones, hilar cholangiocarcinoma, primary sclerosing cholangitis). Ultrasound MBS item 55016; MRCP via referral.

Specialist

Percutaneous liver biopsy

Not required in AMA-positive patients with classic cholestatic biochemistry. Indicated for: (a) AMA-negative / PBC-specific ANA-only patients, (b) suspected PBC-AIH overlap syndrome, (c) atypical presentation. Performed by gastroenterologist/hepatologist.

Available

DEXA bone densitometry

Baseline at diagnosis for osteoporosis screening. MBS item 12320. Repeat every 2 years.

Available

Fat-soluble vitamins (A, D, E, K)

Vitamin D 25-OH (MBS item 66828), vitamin A, E levels. INR to assess vitamin K status. Monitor in all patients, especially with advanced fibrosis or jaundice.

Diagnostic Approach in AMA-Negative Patients

Approximately 5–10% of PBC patients are AMA-negative. In these cases:

Check PBC-specific ANA (anti-sp100 and anti-gp210).
Perform liver biopsy — look for florid duct lesions, granulomatous cholangitis, or bile duct paucity.
Consider MRCP to exclude small-duct primary sclerosing cholangitis (PSC).
AMA-negative PBC responds to UDCA similarly to AMA-positive disease; treat accordingly.

Overlap Syndromes

PBC can coexist with autoimmune hepatitis (PBC-AIH overlap syndrome), occurring in approximately 10% of patients. Suspicion arises when:

ALP <2× ULN but ALT >5× ULN.
IgG >2× ULN.
Biopsy shows significant interface hepatitis alongside bile duct lesions.

Paris criteria and IAIHG scoring systems assist in identifying overlap. Management typically combines UDCA with immunosuppressive therapy (prednisolone ± azathioprine) under hepatologist supervision.

🚨

Important: Never diagnose PBC without excluding extrahepatic biliary obstruction by imaging (ultrasound at minimum). MRCP is recommended if ultrasound is inconclusive or if small-duct PSC overlap is suspected.

Treatment

First-Line: Ursodeoxycholic Acid (UDCA)

💊

Ursodeoxycholic Acid (UDCA)

Ursofalk® · Ursodiol · Hydrophilic bile acid

Adult dose 13–15 mg/kg/day PO in divided doses (BD or TDS). Higher doses (>20 mg/kg/day) do not confer additional benefit.

Paediatric dose 15–20 mg/kg/day PO in 2–3 divided doses (limited data; specialist supervision required).

Route Oral

Duration Lifelong — UDCA should be continued indefinitely. Discontinuation is associated with biochemical and clinical relapse.

Renal adjustment Not required.

Hepatic adjustment Use with caution in decompensated cirrhosis; monitor bilirubin closely.

PBS status ✔ PBS General Benefit

Response Assessment at 12 Months

Biochemical response to UDCA is assessed after 12 months of therapy. Multiple validated criteria exist; the choice depends on clinical context:

Criterion	Definition of Adequate Response	Comment
Paris II	ALP and AST ≤1.5× ULN, and bilirubin ≤1 mg/dL (17 µmol/L)	Widely used in Australian practice; validated long-term prognostic prediction.
POISE criteria	ALP <1.67× ULN AND ≤15% reduction from baseline, OR total bilirubin ≤ ULN	Used in the POISE trial of OCA; gaining traction in Australasia.
GLOBE score	Score <0.30 for patients <65 years; <0.45 for patients ≥65 years	Online calculator available. Incorporates age, ALP, bilirubin, albumin, platelets.
UK-PBC score	Estimated 5-year risk of liver transplant or death <10%	Incorporates ALP, transaminases, bilirubin, albumin, platelets. Online calculator.

Interpretation: Patients achieving an adequate biochemical response have a normalised life expectancy and do not require escalation. Those with an inadequate response (persistent ALP >1.67× ULN and/or elevated bilirubin) should be considered for second-line therapy.

Second-Line Therapy: Obeticholic Acid (OCA)

💊

Obeticholic Acid (OCA)

Ocaliva® · FXR agonist · Farnesoid X receptor agonist

Adult dose Start 5 mg PO daily; increase to 10 mg daily after 3–6 months if tolerated and ALP remains elevated. Always used in combination with UDCA.

Route Oral

Key safety Contraindicated in decompensated cirrhosis (Child-Pugh B/C) or prior decompensation. Can cause severe pruritus (dose-limiting in ~10%). Monitor LFTs monthly for first 3 months.

Renal adjustment No dose adjustment for mild–moderate impairment; avoid in severe impairment (eGFR <15) — limited data.

PBS status Authority Required — PBS-listed for PBC as add-on to UDCA in patients with inadequate response. Authority phone/streamline requirements apply; check current PBS schedule.

🚨

Obeticholic acid — critical safety: OCA is contraindicated in decompensated cirrhosis (Child–Pugh B or C) or patients with a history of decompensation. It can precipitate hepatic failure, liver transplantation, or death. Screen all patients with Child–Pugh score and hepatic synthetic function before initiating. Monthly LFT monitoring for the first 3 months is mandatory.

Off-Label Add-On: Bezafibrate

💊

Bezafibrate

Bezalip® · PPAR-α agonist · Fibrate

Adult dose 400 mg PO daily (modified-release), combined with UDCA. Used off-label in PBC.

Evidence BEZURSO trial: UDCA + bezafibrate achieved biochemical complete response in 67% vs 0% with UDCA alone. Significant improvement in pruritus.

Renal adjustment Contraindicated if eGFR <15 mL/min. Dose reduce to 200 mg/day if eGFR 15–60.

PBS status PBS (indication-specific) — PBS-listed for dyslipidaemia; use in PBC is off-label. Discuss with pharmacy re: cost.

Emerging Agents

Several novel therapies are in late-stage development or recently approved:

Agent	Mechanism	Status	Key Evidence
Seladelpar	Selective PPAR-δ agonist	FDA-approved (Aug 2024). Not yet PBS-listed in Australia.	ENHANCE trial: 61.7% achieved composite response at 12 months vs 20% placebo. Significant ALP reduction and pruritus improvement.
Elafibranor	Dual PPAR-α/δ agonist	FDA-approved (Jun 2024). Not yet PBS-listed in Australia.	ELATIVE trial: 51% composite response at 12 months vs 4% placebo. Robust ALP reduction.

ℹ️

Australian access: Seladelpar and elafibranor are not currently PBS-listed. Patients requiring access may apply through the Special Access Scheme (SAS Category B) or individual hospital pharmacy importation. Discuss with a hepatologist.

Symptom & Complication Management

Pruritus (Itch)

Pruritus affects approximately 20–70% of PBC patients at some point during the disease. It can be debilitating and significantly impairs quality of life. Management follows a stepwise approach:

Step 1

Cholestyramine

4 g PO up to QDS. Take ≥4 hours apart from UDCA and other medications (bile acid sequestrant — binds drugs). Takes 1–2 weeks to assess efficacy.

Setting: Primary care initiation

Step 2

Rifampicin

150–300 mg PO BD. Monitor LFTs weekly for first 4 weeks (hepatotoxicity risk ~12%) and monthly thereafter. Check FBC for thrombocytopenia/haemolytic anaemia.

Setting: Specialist-supervised; requires LFT monitoring

Step 3

Sertraline or Naltrexone

Sertraline 75–100 mg PO daily. Naltrexone 25–50 mg PO daily (start 12.5–25 mg; titrate to reduce opioid-withdrawal-like symptoms). Both have RCT evidence in cholestatic pruritus.

Setting: Specialist or shared care

⚠️

Rifampicin safety: Rifampicin is a potent CYP3A4/P-glycoprotein inducer and interacts with many drugs (warfarin, OCP, statins, calcineurin inhibitors). It can cause hepatotoxicity — monitor LFTs weekly for the first 4 weeks. Rifampicin is available on PBS for pruritus of cholestasis.

Refractory pruritus: For patients unresponsive to the above, consider plasmapheresis, UV-B phototherapy, or referral for liver transplant assessment (pruritus is a valid transplant indication). Emerging data for maralixibat (IBAT inhibitor) in cholestatic pruritus.

Fatigue

Fatigue is the most prevalent symptom of PBC (affecting 50–80% of patients) and is often disproportionate to disease severity. Unfortunately, no pharmacological agent has proven effective.

Modifiable contributors: Screen and treat depression (PHQ-9), hypothyroidism (TFTs), anaemia, obstructive sleep apnoea, coeliac disease, and medication side effects.
Non-pharmacological: Graded exercise programmes, cognitive behavioural therapy, sleep hygiene counselling. Referral to allied health (exercise physiologist, psychologist).
Patient support: PBC Foundation Australia and patient education resources improve coping and self-management.

Osteoporosis Screening & Management

Metabolic bone disease is common in PBC due to cholestasis-induced vitamin D malabsorption, reduced osteoblast activity, and chronic inflammation.

Screening

DEXA scan at diagnosis (MBS item 12320).
Repeat every 2 years.
More frequent if postmenopausal, corticosteroid use, or advanced fibrosis.

Treatment

Calcium 1,000–1,200 mg/day + vitamin D 800–1,000 IU/day supplementation.
Bisphosphonates (alendronate, risedronate) for T-score ≤ −2.5 or FRAX-indicated. Avoid IV bisphosphonates if oesophageal varices (risk of oesophagitis).
Teriparatide or denosumab for refractory osteoporosis under specialist guidance.

Fat-Soluble Vitamin Deficiencies

Bile duct destruction in PBC impairs fat-soluble vitamin absorption (A, D, E, K). Deficiencies are more common with serum bilirubin >2× ULN or advanced fibrosis.

Vitamin	Deficiency Signs	Replacement
Vitamin D	Osteomalacia, osteoporosis, fractures	Cholecalciferol 2,000–10,000 IU/day (titrate to 25-OH-D >75 nmol/L). May require higher doses in malabsorption.
Vitamin A	Night blindness, xerophthalmia	Retinol palmitate 25,000–50,000 IU/day PO; monitor levels to avoid toxicity.
Vitamin E	Ataxia, peripheral neuropathy (rare)	Alpha-tocopherol 400–800 IU/day PO if deficient.
Vitamin K	Coagulopathy (elevated INR)	Phytomenadione (vitamin K1) 10 mg IV/IM if INR prolonged. Maintenance with oral 10 mg weekly or as directed by INR.

Hepatocellular Carcinoma (HCC) Surveillance

PBC-related cirrhosis carries a significant risk of HCC (annual incidence ~1–2%). Surveillance is mandatory:

Who: All PBC patients with established cirrhosis (biopsy-proven or clinical/imaging evidence).
How: 6-monthly abdominal ultrasound ± alpha-fetoprotein (AFP). MBS item 55030.
HCC risk in PBC: Higher in male patients, those with advanced fibrosis (stage 4), and concurrent hepatitis C or metabolic risk factors.

⚠️

HCC surveillance in PBC: Unlike other liver diseases where HCC surveillance begins at cirrhosis diagnosis, in PBC the risk of HCC is primarily in those with stage 4 (cirrhotic) histology. Ensure patients with bridging fibrosis (stage 3) are also discussed with hepatology regarding surveillance initiation.

Liver Transplantation

Liver transplantation is the definitive treatment for end-stage PBC and is associated with excellent outcomes (5-year survival >85%).

Indications: MELD score ≥15, decompensation events (ascites, variceal bleeding, hepatic encephalopathy), HCC meeting Milan criteria, or intractable pruritus.
Recurrence: PBC recurs in 10–30% of transplant recipients, typically 3–7 years post-transplant. Histological recurrence may occur before biochemical changes. UDCA is generally continued post-transplant.
Referral: Refer to a liver transplant centre (Royal Prince Alfred Sydney, Austin Melbourne, Princess Alexandra Brisbane, Sir Charles Gairdner Perth, Flinders Adelaide) when MELD approaches 12–15 or at first decompensation event.
Living donor transplant: Available at select Australian centres; discuss with transplant hepatologist.

Special Populations

🤰 Pregnancy

UDCA

UDCA is generally considered safe in pregnancy (FDA Category B). Continue throughout pregnancy. No known teratogenicity.

Obeticholic acid

Contraindicated in pregnancy. Discontinue and switch to UDCA alone. Counsel regarding contraception.

Bezafibrate

Contraindicated in pregnancy (Category D). Discontinue pre-conception.

Pruritus of pregnancy

Distinguish from intrahepatic cholestasis of pregnancy (ICP). Cholestyramine is first-line. Rifampicin avoided in pregnancy if possible.

👶 Paediatric

Diagnosis

PBC in children is extremely rare. Consider if cholestatic LFTs with AMA positivity. Refer to tertiary paediatric hepatology.

UDCA

15–20 mg/kg/day PO in 2–3 divided doses. Limited paediatric evidence; extrapolated from adult data.

🧓 Elderly

Treatment

UDCA is well tolerated in elderly patients. Monitor for drug interactions (especially cholestyramine). Adjust OCA dosing cautiously.

Osteoporosis

Higher baseline risk — ensure DEXA at diagnosis and aggressive supplementation.

🫘 Renal Impairment

UDCA

No dose adjustment required.

Bezafibrate

Contraindicated if eGFR <15. Dose reduce to 200 mg/day if eGFR 15–60.

OCA

Avoid in severe renal impairment (eGFR <15) — limited data.

🫁 Hepatic Impairment

OCA

Contraindicated in decompensated cirrhosis (Child-Pugh B/C). Can cause hepatic failure. Requires Child-Pugh assessment prior to initiation.

UDCA

Continue; dose adjustment not required but monitor bilirubin for response assessment.

🛡️ Immunocompromised

Considerations

PBC itself is not an immunosuppressive condition. However, concurrent autoimmune overlap may require immunosuppression. Hepatic infections (CMV, VZV) more common post-transplant — monitor closely.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology & prevalence

Data on PBC prevalence in Aboriginal and Torres Strait Islander peoples is limited. Autoimmune liver diseases may be under-recognised due to lower testing rates and diagnostic delays. AIHW data suggest higher rates of chronic liver disease overall in ATSI populations.

Later presentation

ATSI patients may present with more advanced disease due to delayed diagnosis, geographical remoteness, and reduced access to specialist hepatology services. This increases the risk of cirrhosis at first presentation.

Remote & rural access

Specialist hepatology services are concentrated in major metropolitan centres. Telehealth (MBS items 91822, 91823) can facilitate specialist consultation for remote ATSI communities. Royal Flying Doctor Service supports access where available.

Medication access

UDCA is PBS-listed and generally accessible. OCA requires PBS Authority approval — support patients with applications. Pharmacy support via Closing the Gap PBS co-payment measure reduces out-of-pocket costs for eligible ATSI patients.

Cultural safety

Engage Aboriginal Health Workers and Liaison Officers in care planning. Respect cultural protocols and kinship systems in multidisciplinary care. Incorporate yarning and narrative-based approaches in patient education.

Co-morbidities

Higher background rates of metabolic syndrome, diabetes, and chronic kidney disease in ATSI populations may complicate PBC management (e.g., bezafibrate renal contraindications, bone health). Holistic, team-based care is essential.

Referral pathways

Refer to hepatology via local health network pathways. In remote areas, use RHDAustralia resources and the Australian Indigenous HealthInfoNet for culturally appropriate education materials. Aboriginal Community Controlled Health Organisations (ACCHOs) are key partners in chronic disease management.

📚 References

1. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-172.
3. Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631-643.
4. Corpechot C, Chazouillères O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378(23):2171-2181.
5. Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cholangitis: an international follow-up study. Gastroenterology. 2014;147(6):1338-1349.
6. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144(3):560-569.
7. Bowlus CL, Galoosian RJ, Feld JJ, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023;78(2):397-415.
8. Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795-805.
9. Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386(10003):1565-1575.
10. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
11. Australian Indigenous HealthInfoNet. Overview of Aboriginal and Torres Strait Islander health status 2023. Perth: Edith Cowan University; 2023.
12. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871-877.
13. Mayo MJ. Primary biliary cholangitis: narrowing the therapeutic gap. Hepatology. 2021;73(Suppl 1):40-50.
14. Services Australia. Pharmaceutical Benefits Schedule — Obeticholic acid. Canberra: Commonwealth of Australia; 2024. Available from: www.pbs.gov.au
15. Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568-1594.